166 results about "Fixed dose" patented technology

The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.

Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module. In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a three piece capsule, a capsule-in-a-capsule or a tablet-in-a-capsule, and the primary and secondary modules are interchangeable.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

A pharmaceutical composition for oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first and the second pharmaceutical compositions are present in separate entities in a single solid dosage form. For example a multilayer tablet, a two-layer tablet, or capsules or sachets containing the active ingredients in separate granulates or beads, either granulate or bead optionally being coated with a protective coating or an entero-coating.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

A syringe configured with a limited maximum usable capacity. The syringe of the invention desirably has a retractable needle to prevent reuse. In the preferred embodiment, a dose-limiting structure includes a stop-ring member on the head of the plunger that abuts a constriction in the housing when the plunger is moved away from the needle to prevent the further rearward movement of the plunger. Preferably, the syringe of the invention is configured such that a user is tactilely signaled when the plunger has reached a position corresponding to a nominal fixed-dose. If the user attempts to force the stop-ring member beyond the constriction, the plunger seal is stripped off or removed from the plunger head and the syringe rendered inoperable. The features of the invention can also be applied to a nonretracting syringe.

The invention discloses a drug composition for curing tumour diseases, which comprises fixed dose of N-(4-(1-cyanocyclopentyl) phenyl)-2-(4-picolyl) amino-3-pyridinecarboxamide or pharmaceutically acceptable salt of the N-(4-(1-cyanocyclopentyl) phenyl)-2-(4-picolyl) amino-3-pyridinecarboxamide and erlotinib or pharmaceutically acceptable salt of the erlotinib or comprises fixed dose of N-(4-(1-cyanocyclopentyl) phenyl)-2-(4-picolyl) amino-3-pyridinecarboxamide or pharmaceutically acceptable salt of the N-(4-(1-cyanocyclopentyl) phenyl)-2-(4-picolyl) amino-3-pyridinecarboxamide and gefitinib or pharmaceutically acceptable salt of the gefitinib. A method for preparing the drug composition and an application of the drug composition in preparing drugs for curing tumour diseases are further provided.

An injection device incorporating a dose setting mechanism is presented where the dose setting mechanism contains a dose selector having one or more dose stops corresponding to a finite set of predetermined fixed doses, where the set of finite predetermined fixed doses includes a lowest fixed dose and one or more higher fixed doses, and where at least one of the one or more higher fixed doses is equal to the lowest fixed dose plus a fractional amount of the lowest fixed dose. The dose setting mechanism can further include a floating spline that is rotationally engaged with a snap element such that the snap element can rotate relative to the floating spline during both dose setting and dose delivery.

Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

After adding water to the carboxymethyl carrageenan which is raw material and mixing them well, the ionizing radiation of more than fixed dose is irradiated to the obtained paste sample of fixed concentration. As a result, an excellent hydrogel in heat resistance which does not dissolve at 50° C. or more can be obtained. The manufactured gel can be used for many kinds of products. Because this gel has a biodegradation characteristic, it is possible to dispose by composting.

The invention relates to an oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or a pharmaceutically acceptable salt or hydrate thereof, and comprising at least one pharmaceutically acceptable excipient. The composition of the invention can be used e.g. for the treatment of Parkinson's disease.

The invention relates to a medicament compound preparation formed by mixing olmesartan medoxomil with benzene sulfonic acid amlodipine and hydrochlorothiazide. Both the olmesartan medoxomil and amlodipine are unstable compounds, and are difficultly prepared into mixed medicaments with stable active ingredients. According to the invention, the adjuvant of the olmesartan medoxomil and amlodipine compound preparation is regulated, so that the amounts of degradation products and impurities of the olmesartan medoxomil are effectively reduced. The invention provides a method for preparing the fixed-dose compound preparation which takes the olmesartan medoxomil, the amlodipine and hydrochlorothiazide as the active ingredients.

Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

The invention relates to a drug delivery device having a dose limiting system. The drug delivery device includes a first dose setting mechanism (205) operably coupled to a primary reservoir (212) holding a first medicament (214). The first dose setting mechanism includes a first dose setter (208) and is a variable dose setting mechanism. The device further includes a second dose setting mechanism (204) operably coupled to a secondary reservoir (216) holding a second medicament, and the second dose setting mechanism includes a second dose setter (230). Still further, the device includes a dose limiting system (206). The dose limiting system operably couples the variable dose setting mechanism and the fixed dose setting mechanism. Further, the dose limiting system is configured to limit a settable amount of a dose of the second medicament a user can set using the second dose setter based on an amount of a variable dose that a user sets using the first dose setter.

The invention belongs to the technical field of medicines, and provides a compound preparation of antituberculosis medicaments, and a preparation method thereof. Rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride as four leading antituberculosis medicaments are prepared into the compound preparation according to specific mixture ratio. The method comprises the steps of evenly mixing the leading drugs with an appropriate quantity of disintegrant and diluent, performing dry-process granulation, finishing granules, adding other auxiliary materials to the granules and preparing the obtained product into a suitable preparation. The invention solves the problems that patients are difficult to cooperate closely and complete normal chemotherapys because the antituberculosis medicaments are high in dosage, large in dosage form and troublesome in medicine-taking method, and the compound preparation and the preparation method accord with global tuberculosis direct-observation short-range supervision chemotherapy strategy (DOTS) recommended by the WHO. The antituberculosis fixed-dose compound preparation has important significance for simplifying medicine-taking method, carrying out the DOTS and controlling tuberculosis prevalence.